Vaxart Initiates Sentinel Cohort Phase 2b Study Evaluating COVID-19 Oral Pill Vaccine Candidate
Portfolio Pulse from Benzinga Newsdesk
Vaxart has initiated a Phase 2b study to evaluate its oral COVID-19 vaccine pill, comparing it to an approved mRNA vaccine. The study is part of the U.S. government's Project NextGen, with funding up to $456 million.
September 30, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxart has started a Phase 2b study for its oral COVID-19 vaccine pill, which is being compared to an mRNA vaccine. The study is part of Project NextGen, with significant funding from the U.S. government.
The initiation of the Phase 2b study for Vaxart's oral COVID-19 vaccine pill is a significant step forward, potentially increasing investor confidence and interest. The substantial funding from Project NextGen highlights the importance and potential of this development, likely leading to a positive short-term impact on Vaxart's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100